author-photo

Leena Gandhi

Harvard University
New York University

161

Papers

21276

Citations

Citation Trend

Filter By

Papers (161) Sort By

Journal Conference Others

A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer.

2021 Journal of Immunotherapy
Show All
- Source
- Cite
- Save
Citations (1)
Blocking TIM-3 in Treatment-Refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (9)
FP14.15 Neratinib-Based Combination Therapy in HER2-Mutant Lung Adenocarcinomas: Findings from two International Phase 2 Studies

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Phase 1/2 first-in-human (FIH) study of CPI-0209, a novel small molecule inhibitor of enhancer of zeste homolog 2 (EZH2) in patients with advanced tumors.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Safety and antitumor activity of α-PD-L1 antibody as monotherapy or in combination with α-TIM-3 antibody in patients with microsatellite instability-high/mismatch repair-deficient tumors.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (5)
First-In-Human Phase I Study of a Next-Generation, Oral, Transforming Growth Factor-Beta Receptor 1 Inhibitor, LY3200882 in Patients with Advanced Cancer.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Pembrolizumab in Combination with Ipilimumab as Second-Line or Later Therapy for Advanced Non–Small-Cell Lung Cancer: KEYNOTE-021 Cohorts D and H

2019 Lung Cancer
Show All
- Source
- Cite
- Save
Citations (5)
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations

2019 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (51)
24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer

2019 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (126)